Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Characterizing bone metastases and skeletal-related events in patients with well-differentiated neuroendocrine neoplasms utilizing Ga68-DOTATE PET.
Authors
Tucker Coston
Mayo Clinic, Jacksonville, FL;
Tucker Coston , Himil Mahadevia , Marie M. Plante , Joseph M. Accurso , Akash Sharma , Geoffrey Johnson , Jonathan Ben Ashman , Ayse T. Kendi , Mohamad B. Sonbol , Timothy J. Hobday , Thorvardur Ragnar Halfdanarson , Jason S. Starr
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Diagnostics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 641)
DOI
10.1200/JCO.2023.41.4_suppl.641
Abstract #
641
Poster Bd #
G10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Bone metastases and skeletal related events in patients with gastrointestinal neuroendocrine tumors.
First Author: Paula Bruges
Poster
2020 ASCO Virtual Scientific Program
Pretherapeutic 68Ga-DOTATATE PET SUV predictors of survival of radionuclide therapy for metastatic neuroendocrine tumors.
First Author: Rahul Ladwa
Poster
2024 ASCO Genitourinary Cancers Symposium
Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.
First Author: Hong Song
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment.
First Author: Osama M Mosalem